Immunome (NASDAQ:IMNM) Stock Price Down 6.1% – Here’s Why

Immunome, Inc. (NASDAQ:IMNM) shares traded down 6.1% on Tuesday . The stock traded as low as $13.56 and last traded at $13.65. 121,916 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 778,118 shares. The stock had previously closed at $14.53.

Wall Street Analyst Weigh In

IMNM has been the topic of several research analyst reports. Wedbush reaffirmed an “outperform” rating and set a $33.00 price target on shares of Immunome in a research report on Friday, October 25th. Piper Sandler dropped their price target on Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Finally, Stephens assumed coverage on Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $28.83.

Immunome Trading Down 4.7 %

The firm’s fifty day moving average price is $12.22 and its 200 day moving average price is $13.47. The firm has a market capitalization of $863.85 million, a PE ratio of -1.68 and a beta of 1.83.

Insiders Place Their Bets

In related news, insider Robert Lechleider acquired 15,805 shares of the stock in a transaction dated Thursday, November 21st. The shares were acquired at an average price of $9.48 per share, for a total transaction of $149,831.40. Following the completion of the purchase, the insider now owns 15,805 shares in the company, valued at approximately $149,831.40. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CTO Philip Tsai bought 21,000 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The shares were bought at an average price of $9.43 per share, with a total value of $198,030.00. Following the completion of the purchase, the chief technology officer now owns 21,000 shares in the company, valued at approximately $198,030. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 102,862 shares of company stock valued at $978,045 over the last ninety days. Corporate insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Arizona State Retirement System raised its position in Immunome by 9.2% in the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after purchasing an additional 918 shares in the last quarter. Clear Creek Financial Management LLC raised its stake in Immunome by 18.2% during the second quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock worth $317,000 after acquiring an additional 4,035 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Immunome by 34.6% in the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after purchasing an additional 4,129 shares in the last quarter. Cerity Partners LLC grew its holdings in shares of Immunome by 10.5% in the 3rd quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock worth $776,000 after purchasing an additional 5,043 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in shares of Immunome during the 2nd quarter worth about $81,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.